Journal of Clinical Oncology
Articles in this Issue
Mortality caused by coexisting malignant neoplasms and type 2 diabetes mellitus in U.S. adults: A CDC WONDER analysis (1999–2020).
11123 Background: Type 2 diabetes mellitus (T2DM) and malignant neoplasms are among the most prevalent chronic diseases wo...
A kidney-sparing approach using disitamab vedotin plus toripalimab for high-risk upper urinary tract urothelial carcinoma in patients with impaired renal function: Preliminary results from a phase II trial.
e16607 Background: Radical nephroureterectomy (RNU) is the gold standard for high-risk upper urinary tract urothelial carc...
Prognostic impact of tumor recurrence dynamics in patients with HR+/HER2- advanced breast cancer treated with ET+CDK4/6i: Results from the multicenter, Italian study PALMARES-2.
1092 Background: Endocrine sensitivity/resistance (ES/ER) is a key prognostic and predictive factor in patients (pts) with...
Clinical candidate JNC-1043, importin ß inhibitor (first in class), to target incurable cancers, TNBC, and colon cancer.
e15096 Background: JNC-1043 is an importin ß inhibitor, first in class drug candidate for TNBC (triple negative breast can...
Features of euthyroid disorder syndrome in cancer patients with different tumor localizations.
e24093 Background: Euthyroid sick syndrome (ESS) is a complex of thyroid status changes associated with non-thyroidal path...
Preclinical evaluation of intrathecal TRP1-targeted CAR T cells: Effects on durable antitumor immunity in melanoma leptomeningeal disease.
2086 Background: Melanoma leptomeningeal disease (LMD) is fatal, with median survival under 3 months and no effective immu...
Neoadjuvant chemotherapy combined with toripalimab for triple-negative breast cancer: A prospective, single-arm, multi-center study (NEOTORCH-BREAST02).
595 Background: Neoadjuvant de-escalation chemo-immunotherapy with abbreviated cycles remains unclear. We aimed to assess...
The SWOG Mentoring Advanced Practice Providers (MAPP) program.
e21005 Background: Oncology Advanced Practice Providers (APPs), which include Nurse Practitioners (NPs) and Physician Asso...
<i>TP53</i> status and licensing complex/IFNγ transcriptional profiles to stratify endocrine-related outcomes with CDK4/6i exposure in 10,833 real-world ER+/HER2- breast cancers and a treatment-naïve subset.
1032 Background: Endocrine therapy (ET) durability for ER+/HER2- breast cancer (BC) with CDK4/6 inhibitor (CDK4/6i) exposu...
A study of the safety, efficacy, and pharmacokinetics of SPJ-101CA as maintenance therapy for newly diagnosed high-risk neuroblastoma.
10038 Background: Isotretinoin (ISO), an oral vitamin A derivative, induces differentiation of neuroblastoma (NB) cells an...
Real-world outcomes of daratumumab in light-chain amyloidosis patients with advanced renal failure: A TriNetX network study.
e19517 Background: Light-chain (AL) amyloidosis frequently involves the renal and cardiac systems and is associated with h...
Exploration of biomarkers for TRUCE-01: Development of a urine-based efficacy prediction model.
4622 Background: Preliminary results from the TRUCE-01 phase II trial (NCT04730219) indicate encouraging antitumor activit...
Development of an electronic patient navigation platform to enhance adjuvant therapy coordination after cancer surgery.
e13685 Background: For many solid tumors, adjuvant therapy (AT) after curative surgery can reduce recurrence risk and impr...
Temporal trends in gastric cancer incidence by age and sex in the United States.
e16130 Background: The overall incidence of gastric cancer has declined in the United States over recent decades. However,...
Antitumor efficacy of 2-(1,1-Dimethyl-1H-Benzo[e]Indol-2-yl)-5,6,7-trichloro-1,3-tropolone on various models of hepatocellular carcinoma.
e16265 Background: Hepatocellular carcinoma (HCC) is the most common form of liver cancer, for which multikinase inhibitor...
Outcomes of robot-assisted interval debulking surgery in older women with advanced ovarian cancer unfit for laparotomy: A real-world study.
e17600 Background: Older women with advanced epithelial ovarian cancer frequently have comorbidities and frailty that limi...
Long term functional survivorship in oral cavity cancer: Quality of life (QOL) outcomes by return to work (RTW) status.
6107 Background: Long-term survivors of oral cavity cancer (OCC) often experience persistent physical, functional, and psy...
Concordance of measurable residual disease (MRD) rates in the peripheral blood and bone marrow after first-line treatment for CLL with targeted agents: A systematic review and meta-analysis.
e19023 Background: Undetectable measurable residual disease (uMRD) is associated with prolonged progression free survival...
Variability in higher-education support for adolescents and young adults with active cancer: A cross-sectional survey study.
e23279 Background: Adolescents and young adults (AYA) with cancer frequently face disruptions to educational trajectories,...
First data disclosure from the first-in-human phase 1/2 trial of SMP-3124LP, the first investigational pegylated liposome CHK1 inhibitor, in patients with selected advanced solid tumors.
3081 Background: Checkpoint kinase 1 (CHK1) is a critical in the DNA damage response pathway and an important target for a...
5-year overall survival after adjuvant treatment for stage III melanoma: An English nationwide registry-based study.
9570 Background: Adjuvant treatments for stage III cutaneous melanoma were approved based on significant improvement in re...
Understanding the impact of <i>GTF2I</i> mutations in thymic epithelial tumors: Characteristics and clinicogenomic outcomes.
e20173 Background: Thymic epithelial tumors (TETs) are rare malignancies that include thymomas, thymic carcinomas, and thy...
Employment status and occupational patterns among working-age US cancer survivors, 2020-2024.
e23074 Background: Cancer and its treatment often cause impairments constraining work ability, yet financial burdens may c...
From biological complexity to clinical precision: A first-in-class single-patient–level AI strategy for precision drug repurposing in relapsed, refractory, or metastatic cancers using COSMIC mutational signatures with blast-crisis CML as a model.
e15117 Background: Introduction: Relapsed, refractory & metastatic cancers (RRM) are resistant to treatment due to ext...
Analysis of genomic and clinical predictors of overall survival and PSA response: Results from the PRECISION registry.
5051 Background: Outcomes in advanced prostate cancer vary substantially according to clinical and genomic characteristics...